Plate Nº 12 · recorded October 10, 2026
Health & Medicine ResearchReported finding
NEJM Publishes Trial Results for mRNA Seasonal Flu Vaccine in Adults
The New England Journal of Medicine has published trial results on an mRNA seasonal influenza vaccine in adults, reporting data on both efficacy and safety of the technology.
By Elena Vasquez3 min read691 words
In brief
- The New England Journal of Medicine published a study titled "Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults."
- The trial evaluated both the efficacy and the safety of an mRNA-based seasonal flu vaccine in adult participants.
- The full study, including methodology and results, is available at nejm.org.
- mRNA vaccines deliver genetic instructions instead of inactivated virus, allowing faster updating of the vaccine formulation.
The New England Journal of Medicine has published results from a clinical trial titled "Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults," marking a significant step in the effort to apply messenger-RNA technology — the platform behind widely used Covid-19 vaccines — to seasonal influenza.
The trial examined whether an mRNA-based flu vaccine can protect adults against influenza and whether the vaccine is safe to administer. The journal published the full dataset on its website, nejm.org, where the peer-reviewed findings are now available to researchers, clinicians, and the public.
Why does an mRNA flu vaccine matter?
Seasonal influenza remains a persistent public health problem. Current flu vaccines, most of which are produced in chicken eggs or cell cultures, must be redesigned each year to match circulating viral strains. That process takes months, and when the predicted strains match the circulating ones poorly, vaccine effectiveness can drop sharply.
Messenger-RNA vaccines work differently. Instead of delivering weakened or inactivated virus, they deliver genetic instructions — mRNA, a molecule the body reads to build proteins — that teach cells to make a harmless piece of the flu virus. The immune system then learns to recognize and attack the real pathogen.
In plain terms, the technology promises two potential advantages:
- Speed of production: mRNA vaccines can be designed and manufactured quickly, which could allow manufacturers to update the vaccine closer to flu season and respond faster to unexpected strains.
- Potentially better matched protection: because the vaccine is built from genetic code rather than grown in eggs, it may avoid mutations that sometimes occur during egg-based production and weaken the match to circulating viruses.
The technology proved its worth at scale during the Covid-19 pandemic, when mRNA vaccines from Moderna and the Pfizer–BioNTech partnership were deployed to billions of people.
What did the trial test?
According to the published study, researchers evaluated an mRNA seasonal influenza vaccine in adult participants, measuring two things the title of the paper makes explicit: efficacy — how well the vaccine prevented influenza — and safety — the side-effect profile among those who received it.
"Efficacy" in vaccine trials typically refers to a measured reduction in laboratory-confirmed influenza cases among vaccinated participants compared with a control group, while "safety" assessments track adverse events, from common reactions such as injection-site pain and fatigue to rarer complications.
The full methodology — including the number of participants, the age ranges studied, the vaccine dose or doses given, and the exact efficacy figures — appears in the complete paper at nejm.org.
What should readers keep in mind?
Several caveats are standard for a study like this, and readers should weigh the headline findings against them.
First, clinical trial results represent a defined population over a defined period. Flu vaccine performance varies from season to season depending on which strains circulate and how well they match the vaccine's targets.
Second, a single trial, however rigorous, does not settle a scientific question by itself. Independent replication, real-world effectiveness data gathered after any regulatory approval, and longer-term safety monitoring all contribute to the complete picture.
Third, adults are only one segment of the population. Whether the same results would hold in children, older adults with weaker immune responses, or people with chronic medical conditions would require separate study.
Regulatory agencies such as the U.S. Food and Drug Administration would need to review the trial data — and typically additional studies — before any mRNA seasonal flu vaccine could reach the market.
What comes next?
The publication in one of medicine's most influential peer-reviewed journals signals that mRNA influenza vaccination is moving from concept to clinical evidence. If the reported efficacy and safety results hold up in further research, the technology could eventually reshape how the world prepares for each flu season — much as it already has for Covid-19.
For now, the detailed numbers and conclusions live in the journal's pages, where the scientific community will scrutinize, debate, and build upon them. SciBeat readers wanting the complete dataset can consult the study, "Efficacy and Safety of an mRNA Seasonal Influenza Vaccine in Adults," at nejm.org.
via Google News: Clinical Trials (Source)
More from Elena Vasquez
Nearby plates
- AI-Designed RNA Vaccines Stay Stable for a Year at Room Temperature
- mRNA Cancer Vaccine Plus Keytruda Boosts Melanoma Survival
- Nasal Vaccine Additive Kept Mice Alive Against Flu 100 Days Later
- MIT Automates Lipid Nanoparticle Production for RNA Therapies
- MIT team builds method that lets living cells mail out their own RNA